everolimus ratiopharm 10 mg tabletti
ratiopharm gmbh - everolimuusi - tabletti - 10 mg - everolimuusi
gefitinib mylan
mylan pharmaceuticals limited - gefitinib - karsinooma, ei-pienisoluinen keuhko - antineoplastic agents, protein kinase inhibitors - gefitinib mylan on tarkoitettu monoterapiana aikuispotilaille, joilla on paikallisesti edennyt tai metastasoitunut ei‑pienisoluinen keuhkosyöpä (nsclc) kanssa aktivointi mutaatioita egfr‑tk.
gefitinib stada 250 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - gefitinib - tabletti, kalvopäällysteinen - 250 mg - gefitinibi
gefitinib avansor 250 mg tabletti, kalvopäällysteinen
avansor pharma oy - gefitinib - tabletti, kalvopäällysteinen - 250 mg - gefitinibi
gefitinib ratiopharm 250 mg tabletti, kalvopäällysteinen
teva b.v. - gefitinib - tabletti, kalvopäällysteinen - 250 mg - gefitinibi
gefitinib accord 250 mg tabletti, kalvopäällysteinen
accord healthcare b.v. - gefitinib - tabletti, kalvopäällysteinen - 250 mg - gefitinibi
gefitinib orion 250 mg tabletti, kalvopäällysteinen
orion corporation - gefitinibum - tabletti, kalvopäällysteinen - 250 mg - gefitinibi
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
gavreto
roche registration gmbh - pralsetinib - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
roctavian
biomarin international limited - valoctocogene roxaparvovec - hemostaatit - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).